JWATM-214

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameJWATM-214
Drug Alias NameJWATM-214JWATM214
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionGlypican-3 inhibitorsWnt signalling pathway inhibitors
TargetsGlypican-3
Therapy Area/IndicationsLiver NeoplasmsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSuzhou Yaomingjunuo Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesEureka Therapeutics IncLyell Immunopharma IncSuzhou Yaomingjunuo Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLiver NeoplasmsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A